Kucukzeybek Betul Bolat, Bayoglu Ibrahım V, Kucukzeybek Yuksel, Yıldız Yasar, Oflazoglu Utku, Atahan Murat K, Taskaynatan Halıl, Alacacioglu Ahmet, Yigit Seyran, Tarhan Mustafa O
Pol J Pathol. 2018;69(2):157-168. doi: 10.5114/pjp.2018.76699.
Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are more aggressive than other subtypes of breast cancer. Due to the limited number of treatment alternatives and the absence of target receptors in TNBC, and because of progression in the HER2-positive group despite targeted treatments, new treatment targets and therapeutic combinations are required. In this context, the present study aims to evaluate the prognostic importance of immunohistochemical androgen receptor (AR) expression in HER2-positive breast cancer and TNBC subtypes. AR nuclear staining density was evaluated immunohistochemically. A total of 111 operated patients with breast cancer were included in the study; 44 (39.6%) belonged to the HER2-positive breast cancer subgroup and 67 (60.4%) belonged to the TNBC subgroup. AR expression was 34.3% and 79.5% in TNBC and HER2-positive groups, respectively. The 5-year overall survival (OS) was 76% and 58% for the group with an AR-expression > 7.5% and AR-expression < 7.5%, respectively, in the TNBC subgroup (p = 0.042). In the HER2-positive patient group, the subgroups characterised by an AR-expression > 7.5% and AR-expression < 7.5% had 5-year OS rates of 57.6% and 63.5%, respectively (p = 0.91). Including the assessment of AR expression in the routine pathological examination will contribute to our understanding of the relevance of AR in the biology and prognosis of breast cancer.
三阴性乳腺癌（TNBC）和HER2阳性乳腺癌比其他乳腺癌亚型更具侵袭性。由于TNBC的治疗选择有限且缺乏靶受体，以及尽管有靶向治疗但HER2阳性组仍会进展，因此需要新的治疗靶点和治疗组合。在此背景下，本研究旨在评估免疫组织化学雄激素受体（AR）表达在HER2阳性乳腺癌和TNBC亚型中的预后重要性。通过免疫组织化学评估AR核染色密度。共有111例接受手术的乳腺癌患者纳入研究；44例（39.6%）属于HER2阳性乳腺癌亚组，67例（60.4%）属于TNBC亚组。TNBC组和HER2阳性组的AR表达分别为34.3%和79.5%。在TNBC亚组中，AR表达>7.5%和AR表达<7.5%的组5年总生存率（OS）分别为76%和58%（p = 0.042）。在HER2阳性患者组中，AR表达>7.5%和AR表达<7.5%的亚组5年OS率分别为57.6%和63.5%（p = 0.91）。在常规病理检查中纳入AR表达评估将有助于我们理解AR在乳腺癌生物学和预后中的相关性。
